Novavax Inc
NVAX7.440USD
+0.330+4.64%
Close 11/11, 16:00（ET）Quotes delayed by 15 min
1.21BMarket Cap
3.54P/E TTM
More Details of Novavax Inc Company
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Novavax Inc Info
Ticker SymbolNVAX
Company nameNovavax Inc
IPO dateMay 16, 1973
CEOMr. John C. Jacobs
Number of employees952
Security typeOrdinary Share
Fiscal year-endMay 16
Address700 Quince Orchard Road
CityGAITHERSBURG
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code20878
Phone12402682000
Websitehttps://www.novavax.com/?locale=US
Ticker SymbolNVAX
IPO dateMay 16, 1973
CEOMr. John C. Jacobs
Company Executives of Novavax Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
136.73K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
71.31K
+17.11%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
64.76K
+19.18%
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
57.48K
--
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
38.91K
+10.82%
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
36.01K
+40.72%
Ms. Rachel K. King
Ms. Rachel K. King
Independent Director
Independent Director
35.61K
+41.37%
Mr. Mark J. Casey
Mr. Mark J. Casey
Executive Vice President, Chief Legal Officer, Company Secretary
Executive Vice President, Chief Legal Officer, Company Secretary
31.97K
--
Mr. James Patrick (Jim) Kelly
Mr. James Patrick (Jim) Kelly
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
--
--
Dr. Robert Walker, M.D.
Dr. Robert Walker, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
136.73K
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
71.31K
+17.11%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
64.76K
+19.18%
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
57.48K
--
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
38.91K
+10.82%
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
36.01K
+40.72%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q1
No Data
By RegionUSD
Name
Revenue
Proportion
Canada
575.67M
86.38%
Rest of the world
43.29M
6.50%
United States
39.41M
5.91%
Europe
8.09M
1.21%
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.33%
Shah Capital Management, Inc.
7.23%
BlackRock Institutional Trust Company, N.A.
6.87%
Sanofi SA
4.23%
State Street Investment Management (US)
4.20%
Other
68.13%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.33%
Shah Capital Management, Inc.
7.23%
BlackRock Institutional Trust Company, N.A.
6.87%
Sanofi SA
4.23%
State Street Investment Management (US)
4.20%
Other
68.13%
Shareholder Types
Shareholders
Proportion
Investment Advisor
23.38%
Investment Advisor/Hedge Fund
19.07%
Hedge Fund
9.29%
Corporation
8.23%
Research Firm
5.37%
Pension Fund
0.65%
Individual Investor
0.51%
Bank and Trust
0.49%
Insurance Company
0.03%
Other
32.96%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
546
95.10M
58.55%
-6.89M
2025Q2
553
108.80M
66.99%
-11.74M
2025Q1
575
113.82M
70.29%
-16.33M
2024Q4
593
111.51M
69.72%
-5.93M
2024Q3
597
103.31M
64.96%
-4.25M
2024Q2
652
92.80M
65.79%
-10.97M
2024Q1
753
86.51M
64.06%
-11.91M
2023Q4
848
86.68M
74.23%
+6.21M
2023Q3
919
70.31M
60.51%
-6.00M
2023Q2
957
58.87M
62.55%
-19.22M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
15.40M
9.48%
-241.17K
-1.54%
Jun 30, 2025
Shah Capital Management, Inc.
11.51M
7.09%
+379.93K
+3.41%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.17M
6.88%
-388.58K
-3.36%
Jun 30, 2025
Sanofi SA
6.88M
4.24%
--
--
Jun 30, 2025
State Street Investment Management (US)
6.82M
4.2%
-214.91K
-3.05%
Jun 30, 2025
SK Bioscience Co., Ltd.
6.50M
4%
--
--
May 10, 2024
D. E. Shaw & Co., L.P.
3.94M
2.43%
+680.05K
+20.85%
Jun 30, 2025
Coatue Management, L.L.C.
3.84M
2.36%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
3.77M
2.32%
+4.34K
+0.12%
Jun 30, 2025
BofA Global Research (US)
3.14M
1.93%
+1.98M
+171.91%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ProShares Nanotechnology ETF
3.3%
iShares Genomics Immunology and Healthcare ETF
2.89%
Virtus LifeSci Biotech Products ETF
2.02%
ALPS Medical Breakthroughs ETF
0.81%
SPDR S&P Biotech ETF
0.58%
Direxion Daily S&P Biotech Bull 3X Shares
0.3%
ProShares Ultra Nasdaq Biotechnology
0.15%
First Trust Small Cap Growth AlphaDEX Fund
0.15%
Invesco Nasdaq Biotechnology ETF
0.14%
iShares Biotechnology ETF
0.12%
View more
ProShares Nanotechnology ETF
Proportion3.3%
iShares Genomics Immunology and Healthcare ETF
Proportion2.89%
Virtus LifeSci Biotech Products ETF
Proportion2.02%
ALPS Medical Breakthroughs ETF
Proportion0.81%
SPDR S&P Biotech ETF
Proportion0.58%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.3%
ProShares Ultra Nasdaq Biotechnology
Proportion0.15%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.15%
Invesco Nasdaq Biotechnology ETF
Proportion0.14%
iShares Biotechnology ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
